(KIDS) Orthopediatrics - Ratings and Ratios
Implants, Braces, Trauma, Deformity, Scoliosis
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 48.9% |
| Value at Risk 5%th | 76.4% |
| Relative Tail Risk | -5.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.58 |
| Alpha | -46.26 |
| CAGR/Max DD | -0.34 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.478 |
| Beta | 0.998 |
| Beta Downside | 1.147 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.64% |
| Mean DD | 40.66% |
| Median DD | 45.52% |
Description: KIDS Orthopediatrics October 24, 2025
OrthoPediatrics Corp. (NASDAQ: KIDS) designs, develops, and markets a portfolio of anatomically-specific implants, instruments, and braces for children with orthopedic conditions, serving both U.S. and international markets. Its product suite spans pediatric trauma and deformity correction, scoliosis spinal devices, sports-medicine solutions, and growth-modulation systems, including proprietary lines such as PediLoc, the Fassier-Duval telescopic intramedullary system, and the Boston Brace 3D. Founded in 2006 and headquartered in Warsaw, Indiana, the company targets pediatric orthopedic surgeons and caregivers.
Key metrics and sector dynamics that currently shape KIDS’ outlook include: (1) FY 2024 revenue of roughly $115 million, reflecting a 12% year-over-year increase driven by higher adoption of minimally invasive growth-modulation products; (2) a pediatric orthopedic market projected to grow at a 7-9% CAGR through 2030, buoyed by rising incidence of pediatric fractures and expanding insurance coverage for early-intervention surgeries; and (3) regulatory headwinds-each new implant requires FDA 510(k) clearance, which can add 6-12 months to product rollout timelines, creating a material timing risk for pipeline launches.
For a deeper quantitative assessment of KIDS’ valuation assumptions and scenario analysis, the ValueRay platform offers a transparent, data-driven model worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-45.6m TTM) > 0 and > 6% of Revenue (6% = 13.6m TTM) |
| FCFTA -0.06 (>2.0%) and ΔFCFTA 4.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 93.50% (prev 112.7%; Δ -19.16pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.04 (>3.0%) and CFO -19.2m > Net Income -45.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (23.4m) change vs 12m ago 1.08% (target <= -2.0% for YES) |
| Gross Margin 71.73% (prev 73.68%; Δ -1.95pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 46.28% (prev 38.76%; Δ 7.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.30 (EBITDA TTM -14.4m / Interest Expense TTM 5.38m) >= 6 (WARN >= 3) |
Altman Z'' -1.35
| (A) 0.43 = (Total Current Assets 245.9m - Total Current Liabilities 33.2m) / Total Assets 493.5m |
| (B) -0.54 = Retained Earnings (Balance) -265.1m / Total Assets 493.5m |
| (C) -0.07 = EBIT TTM -33.9m / Avg Total Assets 491.4m |
| (D) -1.86 = Book Value of Equity -268.7m / Total Liabilities 144.2m |
| Total Rating: -1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.57
| 1. Piotroski 0.50pt |
| 2. FCF Yield -6.02% |
| 3. FCF Margin -12.94% |
| 4. Debt/Equity 0.28 |
| 5. Debt/Ebitda -5.72 |
| 6. ROIC - WACC (= -15.94)% |
| 7. RoE -12.97% |
| 8. Rev. Trend 95.85% |
| 9. EPS Trend -11.14% |
What is the price of KIDS shares?
Over the past week, the price has changed by +3.59%, over one month by +9.34%, over three months by -13.76% and over the past year by -28.83%.
Is KIDS a buy, sell or hold?
- Strong Buy: 3
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the KIDS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.1 | 30.6% |
| Analysts Target Price | 24.1 | 30.6% |
| ValueRay Target Price | 14.5 | -21.7% |
KIDS Fundamental Data Overview November 25, 2025
P/S = 1.9684
P/B = 1.28
Beta = 1.072
Revenue TTM = 227.4m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -14.4m USD
Long Term Debt = 99.2m USD (from longTermDebt, last quarter)
Short Term Debt = 166.0k USD (from shortTermDebt, last quarter)
Debt = 99.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.5m USD (from netDebt column, last quarter)
Enterprise Value = 489.2m USD (447.6m + Debt 99.3m - CCE 57.7m)
Interest Coverage Ratio = -6.30 (Ebit TTM -33.9m / Interest Expense TTM 5.38m)
FCF Yield = -6.02% (FCF TTM -29.4m / Enterprise Value 489.2m)
FCF Margin = -12.94% (FCF TTM -29.4m / Revenue TTM 227.4m)
Net Margin = -20.06% (Net Income TTM -45.6m / Revenue TTM 227.4m)
Gross Margin = 71.73% ((Revenue TTM 227.4m - Cost of Revenue TTM 64.3m) / Revenue TTM)
Gross Margin QoQ = 73.92% (prev 72.07%)
Tobins Q-Ratio = 0.99 (Enterprise Value 489.2m / Total Assets 493.5m)
Interest Expense / Debt = 1.83% (Interest Expense 1.82m / Debt 99.3m)
Taxrate = 1.05% (-125.0k / -11.9m)
NOPAT = -33.6m (EBIT -33.9m * (1 - 1.05%)) [loss with tax shield]
Current Ratio = 7.40 (Total Current Assets 245.9m / Total Current Liabilities 33.2m)
Debt / Equity = 0.28 (Debt 99.3m / totalStockholderEquity, last quarter 349.3m)
Debt / EBITDA = -5.72 (negative EBITDA) (Net Debt 82.5m / EBITDA -14.4m)
Debt / FCF = -2.80 (negative FCF - burning cash) (Net Debt 82.5m / FCF TTM -29.4m)
Total Stockholder Equity = 351.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.24% (Net Income -45.6m / Total Assets 493.5m)
RoE = -12.97% (Net Income TTM -45.6m / Total Stockholder Equity 351.6m)
RoCE = -7.53% (EBIT -33.9m / Capital Employed (Equity 351.6m + L.T.Debt 99.2m))
RoIC = -7.68% (negative operating profit) (NOPAT -33.6m / Invested Capital 437.3m)
WACC = 8.26% (E(447.6m)/V(547.0m) * Re(9.69%) + D(99.3m)/V(547.0m) * Rd(1.83%) * (1-Tc(0.01)))
Discount Rate = 9.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.43%
Fair Price DCF = unknown (Cash Flow -29.4m)
EPS Correlation: -11.14 | EPS CAGR: 0.0% | SUE: 0.09 | # QB: 0
Revenue Correlation: 95.85 | Revenue CAGR: 27.25% | SUE: -0.91 | # QB: 0
Additional Sources for KIDS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle